Dr. Van Allen is Chief of the Division of Population Sciences at the Dana-Farber Cancer Institute, Associate Professor of Medicine at Harvard Medical School, a clinician at Dana-Farber/Partners Cancer Care, and an Associate Member at the Broad Institute of MIT and Harvard. His research focuses on clinical computational oncology, the application of new technologies to achieve precision cancer medicine, and examining the biological basis of therapy resistance to targeted, chemotherapeutic, and immunologic therapeutics across cancer types. As both a computational biologist and medical oncologist, he has specific expertise in clinical computational oncology and the development of novel algorithms to analyze and interpret molecular data for clinically focused questions. Overall, his research contributes to the field of precision cancer medicine and resistance to targeted therapeutics via expertise and study in translational and clinical bioinformatics. Originally from Los Angeles, CA, he studied Symbolic Systems at Stanford University, obtained his M.D. from UCLA, and completed a residency in internal medicine at UCSF before coming to Boston and completing a medical oncology fellowship at the Dana-Farber/Partners Cancer Care program.